Evaluation of the viability of In-111-labeled DTPA coupled to fibrinogen.
In earlier work, DTPA has been covalently coupled to albumin via the cyclic anhydride of DTPA. Using fibrinogen, we have studied the effect of such coupling on protein viability by both an in vitro and an in vivo assay. Clotting time remained identical to that of the native protein whether the anhydride-to-protein molar ratio was 1:1 or 5:1. In vivo studies were done in dogs, with human fibrinogen labeled with 1-125 and In-111. Throughout 130 hr, blood clearances for the two tracers agreed whether with 1:1 or 5:1 coupling. In a dog model with a thrombogenic catheter, the clot-to-blood ratios for the two radiotracers agreed within experimental error. Finally, 1:1-coupled canine fibrinogen, labeled with In-111, was administered to dogs with a catheter in a jugular vein, and scintigrams at 24 hr clearly showed clotting along the length of the catheter. We conclude that fibrinogen, coupled to DTPA, retains its viability, behaving like radioiodinated fibrinogen in vivo, and In-111 labeled fibrinogen looks promising as a clinical diagnostic agent.
D000818:Animals; D004285:Dogs; D005069:Evaluation Studies as Topic; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D007204:Indium; D007457:Iodine Radioisotopes; D008657:Metabolic Clearance Rate; D004369:Pentetic Acid / Q000378:metabolism*; D013918:Thrombin Time
D007457:Iodine Radioisotopes; D007204:Indium; C020758:indium trichloride; D004369:Pentetic Acid; D005340:Fibrinogen